Safety profile
Explore the established safety profile of Acthar Gel
Flexible dosing allows you to titrate up or down according to your patient’s needs to help achieve treatment goals1
Recommended dosing from the label1
For IS: 150 units/m2 divided into twice-daily intramuscular injections of 75 units/m2 over a 2‑week period*‡
DM/PM=dermatomyositis/polymyositis; IM=intramuscularly; IS=infantile spasms; MS=multiple sclerosis; PsA=psoriatic arthritis; RA=rheumatoid arthritis; SC=subcutaneously; SLE=systemic lupus erythematosus.
*Acthar Gel is provided as either a 5-mL multi-dose vial containing 80 USP units/mL or as a pre-filled self-injection device containing 40 units (0.5 mL) or 80 units (1.0 mL).
†It may be necessary to taper the dose or increase the injection interval to gradually discontinue treatment.
‡Dosing should then be gradually tapered over a 2‑week period to avoid adrenal insufficiency.
Calculate the precise dosage and tapering schedule for your IS patients
§Acthar Gel is provided as either a 5-mL multi-dose vial containing 80 USP units/mL or as a pre-filled self-injection device containing 40 units (0.5 mL) or 80 units (1.0 mL).
||It may be necessary to taper the dose or increase the injection interval to gradually discontinue treatment.
¶Ten of the 11 enrolled patients completed the study. One patient dropped out due to heart block unrelated to the study drug and was not included in the efficacy analysis, as she did not complete the minimum 8 weeks of the study drug required for outcome assessment per study protocol.2
#Patients were administered 80 units, once daily for 14 days.11
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References: